Flunarizine prevents hepatitis C virus membrane fusion in a genotype-dependent manner by targeting the potential fusion peptide within E1

Hepatology

Volumn 63, Issue 1, 2016, Pages 49-62

  Perin, Paula M ^a,b   Haid, Sibylle ^a,b   Brown, Richard J P ^a,b   Doerrbecker, Juliane ^a,b   Schulze, Kai ^b   Zeilinger, Carsten ^c   von Schaewen, Markus ^d   Heller, Brigitte ^d   Vercauteren, Koen ^e   Luxenburger, Eva ^f   Baktash, Yasmine M ^g   Vondran, Florian W R ^b,h   Speerstra, Sietkse ^i,j   Awadh, Abdullah ^i,j   Mukhtarov, Furkat ^i,j   Schang, Luis M ^i,j   Kirschning, Andreas ^c   Müller, Rolf ^f   Guzman, Carlos A ^b   Kaderali, Lars ^k   Randall, Glenn ^g   Meuleman, Philip ^e   Ploss, Alexander ^d   Pietschmann, Thomas ^a,b   more..

^a INSTITUTE OF INFECTION IMMUNOLOGY   (Germany)

^b HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^c LEIBNIZ UNIVERSITY HANNOVER   (Germany)

^d PRINCETON UNIVERSITY   (United States)

^e GHENT UNIVERSITY   (Belgium)

^f SAARLAND UNIVERSITY   (Germany)

^g UNIVERSITY OF CHICAGO   (United States)

^h HANNOVER MEDICAL SCHOOL   (Germany)

ⁱ UNIVERSITY OF ALBERTA   (Canada)

^j UNIVERSITY OF ALBERTA   (Canada)

^k DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FLUNARIZINE; FLUPHENAZINE; GLYCOPROTEIN E1; GLYCOPROTEIN E2; HYBRID PROTEIN; NEUTRALIZING ANTIBODY; PHENOTHIAZINE; PIMOZIDE; PROTEIN ZO1; TRIFLUOPERAZINE; VIRUS FUSION PROTEIN;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; CROSS RESISTANCE; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 5; HEPATITIS C VIRUS GENOTYPE 6; HEPATITIS C VIRUS GENOTYPE 7; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; MEMBRANE FUSION; NONHUMAN; PRIORITY JOURNAL; SCREENING; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS MUTATION; VIRUS REPLICATION; CELL CULTURE; DRUG EFFECTS; GENETICS; GENOTYPE; HEPACIVIRUS;

CELLS, CULTURED; FLUNARIZINE; GENOTYPE; HEPACIVIRUS; HUMANS; VIRAL FUSION PROTEINS; VIRUS INTERNALIZATION;

EID: 84952639370     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.28111     Document Type: Article

References (33)

1. Scheel TK, Rice CM. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med 2013;19:837-849.
2. Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 2014;59:318-327.
3. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001;345:41-52.
4. Pawlotsky JM. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology 2014;146:1176-1192.
5. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013;57:1333-1342.
6. Gentzsch J, Hinkelmann B, Kaderali L, Irschik H, Jansen R, Sasse F, et al. Hepatitis C virus complete life cycle screen for identification of small molecules with pro- or antiviral activity. Antiviral Res 2011;89:136-148.
7. Tscherne DM, Jones CT, Evans MJ, Lindenbach BD, McKeating JA, Rice CM. Time- and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry. J Virol 2006;80:1734-1741.
8. Reiss S, Rebhan I, Backes P, Romero-Brey I, Erfle H, Matula P, et al. Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment. Cell Host Microbe 2011;9:32-45.
9. Tanaka Y, Mori Y, Tani H, Abe T, Moriishi K, Kojima H, et al. Establishment of an indicator cell system for hepatitis C virus. Microbiol Immunol 2010;54:206-220.
10. Chockalingam K, Simeon RL, Rice CM, Chen Z. A cell protection screen reveals potent inhibitors of multiple stages of the hepatitis C virus life cycle. Proc Natl Acad Sci USA 2010;107:3764-3769.
11. Hu Z, Lan KH, He S, Swaroop M, Hu X, Southall N, et al. Novel cell-based hepatitis C virus infection assay for quantitative high-throughput screening of anti-hepatitis C virus compounds. Antimicrob Agents Chemother 2014;58:995-1004.
12. Dorner M, Horwitz JA, Robbins JB, Barry WT, Feng Q, Mu K, et al. A genetically humanized mouse model for hepatitis C virus infection. Nature 2011;474:208-211.
13. Doerrbecker J, Friesland M, Riebesehl N, Ginkel C, Behrendt P, Brown RJ, et al. Incorporation of primary patient-derived glycoproteins into authentic infectious hepatitis C virus particles. Hepatology 2014;60:508-520.
14. Sharma NR, Mateu G, Dreux M, Grakoui A, Cosset FL, Melikyan GB. Hepatitis C virus is primed by CD81 protein for low pH-dependent fusion. J Biol Chem 2011;286:30361-30376.
15. Coller KE, Berger KL, Heaton NS, Cooper JD, Yoon R, Randall G. RNA interference and single particle tracking analysis of hepatitis C virus endocytosis. PLoS Pathog 2009;5:e1000702.
16. Santi CM, Cayabyab FS, Sutton KG, McRory JE, Mezeyova J, Hamming KS, et al. Differential inhibition of T-type calcium channels by neuroleptics. J Neurosci 2002;22:396-403.
17. 2+ channels by Ro 40-5967. Circ Res 1994;75:144-148.
18. Enyeart JJ, Biagi BA, Mlinar B. Preferential block of T-type calcium channels by neuroleptics in neural crest-derived rat and human C cell lines. Mol Pharmacol 1992;42:364-372.
19. Hagiwara N, Irisawa H, Kameyama M. Contribution of two types of calcium currents to the pacemaker potentials of rabbit sino-atrial node cells. J Physiol 1988;395:233-253.
20. Haid S, Novodomska A, Gentzsch J, Grethe C, Geuenich S, Bankwitz D, et al. A plant-derived flavonoid inhibits entry of all HCV genotypes into human hepatocytes. Gastroenterology 2012;143:213-222.
21. Anggakusuma, Colpitts CC, Schang LM, Rachmawati H, Frentzen A, Pfaender S, et al. Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cells. Gut 2013;63:1137-1149.
22. Chamoun-Emanuelli AM, Pecheur EI, Simeon RL, Huang D, Cremer PS, Chen Z. Phenothiazines inhibit hepatitis C virus entry, likely by increasing the fluidity of cholesterol-rich membranes. Antimicrob Agents Chemother 2013;57:2571-2581.
23. Sainz B Jr, Barretto N, Martin DN, Hiraga N, Imamura M, Hussain S, et al. Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat Med 2012;18:281-285.
24. Meertens L, Bertaux C, Dragic T. Hepatitis C virus entry requires a critical postinternalization step and delivery to early endosomes via clathrin-coated vesicles. J Virol 2006;80:11571-11578.
25. Flint M, Thomas JM, Maidens CM, Shotton C, Levy S, Barclay WS, et al. Functional analysis of cell surface-expressed hepatitis C virus E2 glycoprotein. J Virol 1999;73:6782-6790.
26. Kong L, Giang E, Nieusma T, Kadam RU, Cogburn KE, Hua Y, et al. Hepatitis C virus E2 envelope glycoprotein core structure. Science 2013;342:1090-1094.
27. Khan AG, Whidby J, Miller MT, Scarborough H, Zatorski AV, Cygan A, et al. Structure of the core ectodomain of the hepatitis C virus envelope glycoprotein 2. Nature 2014;509:381-384.
28. Garry RF, Dash S. Proteomics computational analyses suggest that hepatitis C virus E1 and pestivirus E2 envelope glycoproteins are truncated class II fusion proteins. Virology 2003;307:255-265.
29. Perez-Berna AJ, Moreno MR, Guillen J, Bernabeu A, Villalain J. The membrane-active regions of the hepatitis C virus E1 and E2 envelope glycoproteins. Biochemistry 2006;45:3755-3768.
30. Lavillette D, Pecheur EI, Donot P, Fresquet J, Molle J, Corbau R, et al. Characterization of fusion determinants points to the involvement of three discrete regions of both E1 and E2 glycoproteins in the membrane fusion process of hepatitis C virus. J Virol 2007;81:8752-8765.
31. Thomas PG, Verkleij AJ. The dissimilar interactions of the calcium antagonist flunarizine with different phospholipid classes and molecular species: a differential scanning calorimetry study. Biochim Biophys Acta 1990;1030:211-222.
32. St Vincent MR, Colpitts CC, Ustinov AV, Muqadas M, Joyce MA, Barsby NL, et al. Rigid amphipathic fusion inhibitors, small molecule antiviral compounds against enveloped viruses. Proc Natl Acad Sci USA 2010;107:17339-17344.
33. Colpitts CC, Ustinov AV, Epand RF, Epand RM, Korshun VA, Schang LM. 5-(Perylen-3-yl)ethynyl-arabino-uridine (aUY11), an arabino-based rigid amphipathic fusion inhibitor, targets virion envelope lipids to inhibit fusion of influenza virus, hepatitis C virus, and other enveloped viruses. J Virol 2013;87:3640-3654.